Small molecule therapeutics alter the three-dimensional landscape of glutamate receptors to control neurotransmission in disease states. We outline how therapeutic candidates inhibit glutamate receptors, and also observe a new phenomenon called allosteric competition, where two small molecules compete to control receptor function. Our findings provide a new framework for us to understand three-dimensional control of receptor function and provide new foundations for rational drug design. Read more in our preprint, linked below!
https://www.biorxiv.org/content/10.1101/2023.11.28.569057v1